O	0	1	A
O	2	13	prospective
O	14	24	randomized
O	25	30	trial
O	31	40	comparing
B-intervention	41	47	patent
I-intervention	48	52	blue
O	53	56	and
B-control	57	66	methylene
I-control	67	71	blue
O	72	75	for
O	76	79	the
O	80	89	detection
O	90	92	of
O	93	96	the
O	97	105	sentinel
O	106	111	lymph
O	112	116	node
O	117	119	in
O	120	126	breast
O	127	133	cancer
O	134	142	patients
O	142	143	.

O	144	153	Methylene
O	154	158	blue
O	159	161	is
O	162	166	more
O	167	173	widely
O	174	183	available
O	184	187	and
O	188	192	less
O	193	202	expensive
O	203	207	than
O	208	214	patent
O	215	219	blue
O	219	220	,
O	221	225	with
O	226	228	an
O	229	239	apparently
O	240	245	lower
O	246	250	risk
O	251	253	of
O	254	265	anaphylaxis
O	265	266	.

O	267	270	The
O	271	274	two
O	275	279	dyes
O	280	284	were
O	285	293	compared
O	294	303	regarding
O	304	313	detection
O	314	316	of
O	317	320	the
O	321	329	sentinel
O	330	335	lymph
O	336	340	node
O	341	342	(
O	342	345	SLN
O	345	346	)
O	346	347	.

O	348	349	A
O	350	361	prospective
O	361	362	,
O	363	373	randomized
O	374	379	trial
O	380	388	involved
B-total-participants	389	392	142
B-eligibility	393	401	patients
I-eligibility	402	406	with
I-eligibility	407	415	invasive
I-eligibility	416	422	breast
I-eligibility	423	432	carcinoma
O	432	433	.

B-intervention-participants	434	439	Sixty
I-intervention-participants	439	440	-
I-intervention-participants	440	444	nine
O	445	446	(
O	446	448	49
O	448	449	.
O	449	450	3
O	450	451	%
O	451	452	)
O	453	461	assigned
O	462	464	to
O	465	471	patent
O	472	476	blue
O	477	478	(
O	478	483	group
O	484	485	A
O	485	486	)
O	487	490	and
B-control-participants	491	493	71
O	494	495	(
O	495	497	50
O	497	498	.
O	498	500	70
O	500	501	%
O	501	502	)
O	503	505	to
O	506	515	methylene
O	516	520	blue
O	521	522	(
O	522	527	group
O	528	529	B
O	529	530	)
O	530	531	.

O	532	538	Thirty
O	538	539	-
O	539	543	five
O	544	552	patients
O	553	554	(
O	554	556	25
O	556	557	.
O	557	558	0
O	558	559	%
O	559	560	)
O	561	565	were
O	566	574	clinical
O	575	580	stage
O	581	584	III
O	585	587	or
O	588	590	IV
O	590	591	;
O	592	594	55
O	595	596	(
O	596	598	38
O	598	599	.
O	599	600	7
O	600	601	%
O	601	602	)
O	603	606	had
O	607	615	axillary
O	616	621	lymph
O	622	627	nodes
O	628	636	affected
O	636	637	;
O	638	641	and
O	642	644	69
O	645	646	(
O	646	648	49
O	648	649	.
O	649	650	3
O	650	651	%
O	651	652	)
O	653	662	underwent
O	663	674	neoadjuvant
O	675	687	chemotherapy
O	687	688	.

O	689	692	Two
O	693	701	patients
O	702	706	were
O	707	715	excluded
O	716	723	because
O	724	727	the
O	728	731	dye
O	732	736	type
O	737	740	was
O	741	744	not
O	745	753	recorded
O	753	754	.

O	755	763	Patients
O	764	767	and
O	768	773	tumor
O	774	789	characteristics
O	790	794	were
O	795	802	similar
O	803	805	in
O	806	810	both
O	811	817	groups
O	817	818	.

B-outcome	819	823	SLNs
I-outcome	824	828	were
I-outcome	829	839	identified
O	840	842	in
B-iv-bin-abs	843	845	47
O	846	851	women
O	852	853	(
B-iv-bin-percent	853	855	68
I-iv-bin-percent	855	856	.
I-iv-bin-percent	856	857	1
I-iv-bin-percent	857	858	%
O	858	859	)
O	860	862	in
O	863	868	group
O	869	870	A
O	871	874	and
B-cv-bin-abs	875	877	43
O	878	879	(
B-cv-bin-percent	879	881	60
I-cv-bin-percent	881	882	.
I-cv-bin-percent	882	883	6
I-cv-bin-percent	883	884	%
O	884	885	)
O	886	888	in
O	889	894	group
O	895	896	B
O	897	898	(
O	898	899	p
O	899	900	=
O	900	901	0
O	901	902	.
O	902	904	35
O	904	905	)
O	905	906	.

B-outcome	907	911	SLNs
I-outcome	912	916	were
I-outcome	917	925	affected
O	926	928	in
B-iv-bin-abs	929	931	22
O	932	937	cases
O	938	939	(
B-iv-bin-percent	939	941	51
I-iv-bin-percent	941	942	.
I-iv-bin-percent	942	943	2
I-iv-bin-percent	943	944	%
O	944	945	)
O	946	948	in
O	949	954	group
O	955	956	A
O	957	960	and
B-cv-bin-abs	961	963	21
O	964	965	(
B-cv-bin-percent	965	967	48
I-cv-bin-percent	967	968	.
I-cv-bin-percent	968	969	8
I-cv-bin-percent	969	970	%
O	970	971	)
O	972	974	in
O	975	980	group
O	981	982	B
O	983	984	(
O	984	985	p
O	985	986	=
O	986	987	0
O	987	988	.
O	988	990	62
O	990	991	)
O	991	992	.

O	993	996	The
B-outcome	997	1000	SLN
I-outcome	1001	1004	was
I-outcome	1005	1008	the
I-outcome	1009	1013	only
I-outcome	1014	1018	node
I-outcome	1019	1027	affected
O	1028	1030	in
B-iv-bin-abs	1031	1033	12
O	1034	1039	cases
O	1040	1041	(
B-iv-bin-percent	1041	1043	54
I-iv-bin-percent	1043	1044	.
I-iv-bin-percent	1044	1045	5
I-iv-bin-percent	1045	1046	%
O	1046	1047	)
O	1048	1050	in
O	1051	1056	group
O	1057	1058	A
O	1059	1062	and
B-cv-bin-abs	1063	1066	six
O	1067	1068	(
B-cv-bin-percent	1068	1070	33
I-cv-bin-percent	1070	1071	.
I-cv-bin-percent	1071	1072	3
I-cv-bin-percent	1072	1073	%
O	1073	1074	)
O	1075	1077	in
O	1078	1083	group
O	1084	1085	B
O	1086	1087	(
O	1087	1088	p
O	1088	1089	=
O	1089	1090	0
O	1090	1091	.
O	1091	1093	18
O	1093	1094	)
O	1094	1095	.

O	1096	1099	The
O	1100	1104	time
O	1105	1108	and
O	1109	1115	degree
O	1116	1118	of
O	1119	1129	difficulty
O	1130	1138	involved
O	1139	1141	in
O	1142	1153	identifying
O	1154	1157	the
O	1158	1161	SLN
O	1162	1166	were
O	1167	1174	similar
O	1175	1177	in
O	1178	1182	both
O	1183	1189	groups
O	1189	1190	.

O	1191	1196	There
O	1197	1201	were
O	1202	1204	no
O	1205	1218	complications
O	1219	1221	or
O	1222	1231	allergies
O	1231	1232	.

O	1233	1242	Methylene
O	1243	1247	blue
O	1248	1257	performed
O	1258	1260	as
O	1261	1265	well
O	1266	1268	as
O	1269	1275	patent
O	1276	1280	blue
O	1281	1283	in
O	1284	1295	identifying
O	1296	1299	the
O	1300	1303	SLN
O	1304	1306	in
O	1307	1313	breast
O	1314	1320	cancer
O	1321	1329	patients
O	1329	1330	.
